Accelerated Biosciences Corp.
Accelerated Biosciences is dedicated to revolutionizing regenerative medicine by leveraging the natural abilities of human trophoblast stem cells (hTSCs). Their mission is to develop innovative therapies for treating diseases, repairing organs, and improving patient outcomes through ethical sourcing, advanced platforms, and a strong commitment to scientific excellence. They focus on creating a robust ecosystem of stem cell platforms, patents, collaborations, and partnerships to accelerate the development, commercialization, and application of regenerative therapies and biomanufacturing solutions.
Industries
Nr. of Employees
small (1-50)
Accelerated Biosciences Corp.
Los Angeles, California, United States, North America
Products
GMP-eligible hTSC cell lines and RUO counterparts
Banks of human trophoblast stem cell lines available as GMP-eligible clinical starting materials and matched research-use-only lines for discovery and development.
hTSC-derived iPSC clones (mRNA-reprogrammed)
Induced pluripotent stem cell clones reprogrammed from hTSC starting material using non-integrating mRNA methods.
hTSC-derived exosome preparations
Standardized exosome products derived from hTSCs offered with consistent CMC attributes and described high purity for research and development.
Precision genome engineering services and multi-site edited cell lines
Genetic engineering services enabling multi-site targeted edits and creation of engineered cell lines for diverse applications including cell therapies and complex protein expression.
Licensed trophoblast-derived manufacturing cell lines (partnered)
Cell lines licensed to third-party partners to develop ethically sourced manufacturing platforms for research and biomanufacturing applications.
Partner-generated clinical-grade iPSC lines
Clinical-grade iPSC lines produced through collaborative reprogramming programs from early-stage trophoblast-derived sources using non-integrating, clinical workflows.
GMP-eligible hTSC cell lines and RUO counterparts
Banks of human trophoblast stem cell lines available as GMP-eligible clinical starting materials and matched research-use-only lines for discovery and development.
hTSC-derived iPSC clones (mRNA-reprogrammed)
Induced pluripotent stem cell clones reprogrammed from hTSC starting material using non-integrating mRNA methods.
hTSC-derived exosome preparations
Standardized exosome products derived from hTSCs offered with consistent CMC attributes and described high purity for research and development.
Precision genome engineering services and multi-site edited cell lines
Genetic engineering services enabling multi-site targeted edits and creation of engineered cell lines for diverse applications including cell therapies and complex protein expression.
Licensed trophoblast-derived manufacturing cell lines (partnered)
Cell lines licensed to third-party partners to develop ethically sourced manufacturing platforms for research and biomanufacturing applications.
Partner-generated clinical-grade iPSC lines
Clinical-grade iPSC lines produced through collaborative reprogramming programs from early-stage trophoblast-derived sources using non-integrating, clinical workflows.
Services
Supply of research-use and GMP-grade starting materials
Provision of RUO and GMP-eligible hTSC cell lines, hTSC-derived iPSC clones and exosomes with options for commercial licensing and certificates of analysis.
Platform licensing and IP partnerships
Licensing of patent-covered trophoblast-derived cell technologies and associated know-how to enable partner freedom-to-operate and product development.
Translational development and CDMO integration support
Support services to connect partners with CDMOs, provide process designs and de-risk GMP/CMC starting-material issues to accelerate IND-enabling studies and commercialization.
Collaborative academic research partnerships
Collaborations with academic institutions including donations of research-use materials and joint preclinical research to advance basic and translational trophoblast-derived cell science.
Partnered licensing and commercialization support for manufacturing cell lines
Licensing of trophoblast-derived cell lines to external biomanufacturing partners and support for downstream commercialization and platform deployment.
Collaborative immuno-oncology R&D partnerships
Joint development programs with industry and research institutes to evaluate and engineer trophoblast-derived effector cells for cancer and infectious-disease applications.
Supply of research-use and GMP-grade starting materials
Provision of RUO and GMP-eligible hTSC cell lines, hTSC-derived iPSC clones and exosomes with options for commercial licensing and certificates of analysis.
Platform licensing and IP partnerships
Licensing of patent-covered trophoblast-derived cell technologies and associated know-how to enable partner freedom-to-operate and product development.
Translational development and CDMO integration support
Support services to connect partners with CDMOs, provide process designs and de-risk GMP/CMC starting-material issues to accelerate IND-enabling studies and commercialization.
Collaborative academic research partnerships
Collaborations with academic institutions including donations of research-use materials and joint preclinical research to advance basic and translational trophoblast-derived cell science.
Partnered licensing and commercialization support for manufacturing cell lines
Licensing of trophoblast-derived cell lines to external biomanufacturing partners and support for downstream commercialization and platform deployment.
Collaborative immuno-oncology R&D partnerships
Joint development programs with industry and research institutes to evaluate and engineer trophoblast-derived effector cells for cancer and infectious-disease applications.
Expertise Areas
- Regenerative medicine
- Stem cell line development and banking
- Cell therapy CMC and GMP manufacturing
- Exosome therapeutics and characterization
Key Technologies
- Human trophoblast stem cell (hTSC)-derived cell lines
- mRNA-based iPSC reprogramming
- Exosome isolation and CMC-standardized production
- Multi-site targeted genome engineering (non-random insertion)